HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: For instance, Vorinostat is a class I and II histone deacetylase (HDAC) inhibitor that is efficacious against cutaneous T cell lymphoma [301], and Onureg is used to treat acute myeloid leukemia by preventing DNA methylation through inhibition of DNA methyltransferase [302].